“We can’t take the orphan drug revolution for granted.“ Biorasi’s Few & Far Between Podcast welcomes Jim Geraghty, author and biotech industry veteran, to discuss the necessity and viability of orphan and rare disease research - for both patients and VC investors alike.
“Our studies are open for those that have exhausted standard of care, and we're showing improved responses, and the data is promising. So, I...
Today on the Biorasi Few & Far Between podcast: What's trending in the CRO market? Find out as host Melissa Alesse welcomes Joel White,...
Is the epigenome the "software" of the cell nucleus? Find out in our latest episode of the Biorasi Few & Far Between podcast! Host...